PD-L1 expression in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy.

被引：0
|
作者：
Mamesaya, Nobuaki
Kenmotsu, Hirotsugu
Miyawaki, Eriko
Kotake, Mie
Kawamura, Takahisa
Kobayashi, Haruki
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e20530
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20530
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy
    Vrankar, Martina
    Kern, Izidor
    Stanic, Karmen
    RADIATION ONCOLOGY, 2020, 15 (01)
  • [2] Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy
    Martina Vrankar
    Izidor Kern
    Karmen Stanic
    Radiation Oncology, 15
  • [3] PD-L1 expression and survival in stage III unresectable non-small cell lung cancer patients in Denmark
    Cronin-Fenton, D.
    Dalvi, T.
    Movva, N.
    Pedersen, L.
    Hansen, H.
    Fryzek, J.
    Mellemgaard, A.
    Rasmussen, T.
    Klein, A. B.
    Hamilton-Dutoit, S.
    Norgaard, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S808 - S808
  • [4] Retrospective analysis between PD-L1 expression and prognosis for stage III non-small cell lung cancer patients who received concurrent chemoradiotherapy.
    Tokito, Takaaki
    Azuma, Koichi
    Ishii, Hidenobu
    Yamada, Kazuhiko
    Hoshino, Tomoaki
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] PD-L1 expression, EGFR and KRAS mutations in unresectable stage III non-small cell lung cancer (NSCLC) patients
    Cronin-Fenton, Deirdre
    Dalvi, Tapashi
    Hedgeman, Elizabeth
    Norgaard, Mette
    Pedersen, Lars
    Hansen, Hanh
    Fryzek, Jon
    Walker, Jill
    Mellemgaard, Anders
    Rasmussen, Torben
    Shire, Norah
    Riggas, James
    Potter, Danielle
    Hamilton-Dutoit, Stephen
    Sorensen, Henrik
    CANCER RESEARCH, 2018, 78 (13)
  • [6] PD-L1 expression on tumor cells as a potential predictive biomarker for patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
    Kaesmann, Lukas
    Nieto, Alexander
    Taugner, Julian
    Manapov, Farkhad
    TRANSLATIONAL CANCER RESEARCH, 2023, 12 (04) : 705 - 708
  • [7] PD-L1 Expression in Patients with Non-small Cell Lung Cancer
    Masago, Katsuhiro
    Fujita, Shiro
    Hata, Akito
    Okuda, Chiyuki
    Kaji, Reiko
    Katakami, Nobuyuki
    Hirata, Yukio
    ANTICANCER RESEARCH, 2017, 37 (05) : 2269 - 2274
  • [8] Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer
    Vokes, EE
    Crawford, J
    Bogart, J
    Socinski, MA
    Clamon, G
    Green, MR
    CLINICAL CANCER RESEARCH, 2005, 11 (13) : 5045S - 5050S
  • [9] Prognostic significance of PD-L1 expression combined with CD8+TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy
    Matsuo, N.
    Tokito, T.
    Azuma, K.
    Ishii, H.
    Yamada, K.
    Hoshino, T.
    ANNALS OF ONCOLOGY, 2015, 26 : 129 - 129
  • [10] Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
    Mooradian, Meghan J.
    Cai, Ling
    Wang, Alice
    Qiao, Yao
    Chander, Pratibha
    Whitaker, Ryan M.
    JAMA NETWORK OPEN, 2024, 7 (04) : e247542
12345